Perth
Perth
Perth, Washington, Australia7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children | Infections | Recruiting | Phase 4 | 2026-10-09 | NCT04876131 | |
| A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Fabry disease, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, hereditary disease, inborn errors of metabolism, kidney disorder, kidney failure, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-07-06 | NCT04020055 | |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-04-30 | NCT06051409 | |
| The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT05756322 | |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-02-20 | NCT05991388 | |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-02-17 | NCT05987332 | |
| Phase III Trial of Sirolimus in IBM | inclusion body myositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 3 | 2026-01-14 | NCT04789070 |